Investment fuels expansion of breakthrough platform that lets brands test and validate pricing in minutes, not months

STOCKHOLM, May 6, 2025 — Priceagent, the platform rewriting the rules of pricing strategy, has raised $550,000 in seed funding backed by its founders, expert consultants, and notable angel investors including former Cint executives. The funding will accelerate hiring, and expand sales and the global rollout of its intuitive self-serve platform, built to arm brands with the urgent pricing insights they need to thrive. This is especially critical as economic volatility, supply chain disruption, and the introduction of new tariffs have made it more difficult for companies to price effectively.

“Too many brands are still pricing by habit, by hope, or by copying competitors,” said Robert Tinterov, CEO and co-founder of Priceagent. “That doesn’t cut it anymore. We’re here to put an end to ‘hope-and-copy’ pricing and show companies exactly what they should charge, based on real customer willingness to pay, not guesswork. As trade wars intensify, this information is needed more than ever.”

Priceagent was born out of a simple but urgent truth: pricing is the single most powerful lever for profit, yet most companies treat it like a shot in the dark. In a global economy rocked by tariffs, inflation and supply chain shocks, waiting months for consultants or POS data is too slow, and too risky.

The Priceagent platform gives teams the ability to run price sensitivity tests in minutes, using real consumer feedback. With a full view of the demand landscape, demand plateaus, price walls, and everything between, brands can design pricing strategies that grow revenue, demand, or market share with confidence. It’s fast, intelligent, and puts pricing control back in the hands of companies – even for those that have previously lacked the tools or processes to handle it themselves.

Seasoned tech entrepreneur Emanuel Lipschütz, who invested in this latest round in addition to a previous round, spoke of his continued commitment to the company and his belief in Priceagent’s unique offer: “Having worked in the business of designing and securing critical IT infrastructure within a wide range of sectors, turning complex challenges into scalable solutions and leading high-stakes digital transformation projects, I’m keen to support this venture. Priceagent is set to transform the modern-day landscape of pricing intelligence, solving a real business problem at a critical time.”

The seed round closed ahead of schedule due to strong interest from investors who saw both the market need and early traction. Priceagent is already being used by more than 1,500 brands across 45+ countries, including Ticketmaster, Electrolux, Circana, Tripadvisor, Skanska, Marley Spoon, and Bridgestone Golf.

“We’re turning years of consulting expertise into scalable tech,” added Tinterov. “And we’re just getting started. This funding lets us bring that power to more teams, more quickly.”

About Priceagent
Priceagent is a self-serve pricing platform that helps SMEs and global enterprises confidently set prices by showing exactly how many customers would buy at each price, and how demand shifts across factors like product feature, sales channel, competitor positioning, and more.

Headquartered in Stockholm with an office in Los Angeles, Priceagent gives brands real-time access to buyer willingness-to-pay across 130+ markets, drawn from a pool of over 300 million verified consumers worldwide. Its proprietary algorithm, perfected over 10 years, reveals safe price plateaus, sharp demand drop-offs, and competitor benchmarks. Enabling faster, cheaper, and repeatable pricing decisions without relying on slow, costly traditional research methods.

Learn more at www.priceagent.com.

Media contact: Robert Tinterov, [email protected], +46702407790

SOURCE Priceagent

SAN FRANCISCO, May 6, 2025 — Intercept Music, a leader in technology-driven independent music distribution and marketing, has fortified its commitment to reshaping the industry with the completion of a $50 million private partnership for strategic music catalog purchases. Founder and chairman, Ralph Tashjian and CEO, Tod Turner, have announced that the new funding, earmarked for the acquisition of U.S. and Latin music catalogs, is in alignment with the company’s vision to be the go-to portal and resource for independents around the globe, and will significantly uplift streaming, sync, and licensing revenues post-acquisition.

The partnership includes provisions for flexible deal structuring, allowing Intercept to acquire full or partial rights while maintaining synergy with original creators and rights holders.  By acquiring catalogs with untapped or under-leveraged revenue potential, Intercept aims to use its proprietary technology, predictive analytics and targeted marketing portal to amplify both earnings and audience reach across streaming and digital channels. The designated funding will drive catalog acquisitions and enable Intercept Music to expand catalog management operations, furthering its mission of empowering rights holders with transparent, data-driven tools.

“This is more than just a funding deal—it’s a commitment to restructuring music rights management,” cites Tod Turner, CEO of Intercept Music. “This partnership is a significant endorsement of our platform and strategy allowing us to combine capital with cutting-edge technology to unlock more value for artists, songwriters, and catalog owners, while accelerating our growth into the Latin and U.S. markets.”

“This is a bold statement about Intercept’s vision for the future of music catalog management,” notes Intercept Music founder and chairman Ralph Tashjian, a co-investor and strategic advisor in the partnership. “By pairing institutional-grade funding with our technology driven distribution and marketing platform, Intercept is establishing a new standard for how catalogs are valued, managed, and monetized.”

Intercept’s catalog management division will begin deploying capital immediately, with several initial acquisitions already under review.

About Intercept Music Inc.

Intercept Music empowers independent artists and labels with innovative entertainment technology. The company provides cutting-edge tools and services for premium distribution, dynamic social media, targeted marketing, impactful merchandising, and customizable promotional services. Intercept’s technology grants artists access to a wealth of AI-powered features, enabling them to use predictive marketing to optimize their promotional efforts and directly connect with their target audiences. Designed specifically for the booming independent music sector, Intercept Music helps artists grow their audiences and generate revenue.

Discover more at interceptmusic.com or visit Intercept Music on Instagram, Twitter, and Facebook.

Contact:

Makeda Smith / Jazzmyne Public Relations/ 661-212-7655

SOURCE Intercept Music

Led by Brighton Park Capital, the investment will fuel further development of autonomous maritime technology, driving operational efficiency and sustainability across the global shipping industry

LONDON, May 6, 2025 — Orca AI, a leader in maritime technology, today announced it has closed an investment of $72.5 million in Series B funding. Brighton Park Capital led the round with participation from existing investors Ankona Capital and Hyperlink Ventures. The investment will enable Orca AI to further its autonomous platform, add new capabilities and enter new categories, including defense and security. The funding will also strengthen the company’s position as the market leader in autonomous shipping. The completion of this round brings Orca AI’s total funding raised to $111 million with OCV Partners and Mizmaa Ventures also participating in previous rounds.

Founded in 2018 by CEO Yarden Gross and CTO Dor Raviv, Orca AI is revolutionizing the traditionally opaque, conservative shipping industry with AI-powered decision making and autonomous shipping capabilities. The company has the world’s largest marine visual dataset, built from over 80 million nautical miles. Powered by advanced AI and computer vision, this dataset forms the foundation for unmatched situational awareness capabilities in ocean navigation, helping captains and crew members identify risks and targets that cannot be spotted with the human eye. By delivering AI-based alerts and recommendations, Orca AI is able to significantly reduce the probability of collisions that have a severe economic and human impact, so crews can focus their attention on the most critical parts of their voyages.

Orca AI’s technology delivers significant improvements in operational decision-making and voyage safety. A 2024 analysis of Orca AI’s alerts system showed a 54% reduction in close encounter events, which improved overall safety and reduced associated accelerations. In turn, this led to an average of $100,000 savings in fuel per vessel per year – translating to a total estimated reduction of 195,000 tons in CO2 emissions in 2024. 

“At Orca AI, we are constantly pushing the boundaries of what is possible when AI supports human decision-making at sea,” said Yarden Gross, CEO and Co-Founder of Orca AI. “Over the past two years, ships have become increasingly connected to the cloud, enabling large-scale data collection and unlocking the potential of AI. Orca AI is leading this transformation, deploying advanced AI technologies that make vessels smarter, safer, and more automated. We are grateful to have forward-thinking investors who, like us, can see how the advancements in AI and connectivity are opening up new opportunities to enhance autonomous shipping, which will define the future of maritime operations.”

“By combining innovation and deep maritime industry expertise, Orca AI is setting a new standard for the shipping industry, driving remarkable advancements to dramatically improve nautical safety and operations, while charting the course towards autonomous shipping,” said Ezra Berman, Vice President at Brighton Park Capital.

Sam Kentor, Partner at Brighton Park Capital, continued, “At Brighton Park, we are proud to support founder-led companies like Orca AI that harness frontier technology to address complex challenges and deliver real impact. We look forward to collaborating with the Orca AI team as they build a more resilient global supply chain.”

Orca AI’s platform is already trusted by major global shipping companies, including MSC, NYK, Scorpio, and Seaspan. By helping mitigate accidents and operational issues, Orca AI enables hundreds of vessels to save billions of dollars in potential damage each year. The significant improvement in connectivity in remote waters, driven by satellite-based services like Starlink, allows real-time data to be transmitted to Orca AI for mapping routes, traffic monitoring, and sharing critical information. This capability is key to developing autonomous navigation, providing an unprecedented level of precision in vessel monitoring.

For more information about Orca AI and its autonomous maritime technology, visit www.orca-ai.io.

About Orca AI

Orca AI is the leading maritime operations platform utilizing artificial intelligence and computer vision to achieve the most significant change across the shipping industry in centuries. The Orca AI platform empowers shipping companies to maximize operational efficiency and voyage safety for ships and fleets. With Orca AI, crew can now make rapid, data-driven decisions in congested waters or low visibility conditions, while fleet managers and operators gain unprecedented insights into their fleets’ performance.

Orca AI brings autonomous mobility to the shipping industry, having powered the world’s first commercial autonomous voyage in 2022, in partnership with Designing the Future of Full Autonomous Ships (DFFAS) and The Nippon Foundation.

Headquartered in London, UK, Orca AI is trusted by global leaders including Maran Tankers, MSC, Seaspan and NYK, with more than 1,200 vessels booked with the platform.

https://www.orca-ai.io/

About Brighton Park Capital

Brighton Park Capital is a New York-based investment firm focused on entrepreneur-led, growth-stage software, healthcare and tech-enabled services companies. The firm invests in companies that provide highly innovative solutions in partnership with great management teams. Brighton Park brings purpose-built, value-add capabilities that match the unique requirements of each of its companies. For more information about Brighton Park Capital, please visit www.bpc.com.

Media Contacts

Orca AI 

Mushkie Meyer
[email protected]
US: +1 914 336 4035
UK: +44 203 769 4034

Brighton Park Capital

FGS Global
[email protected] 

SOURCE Orca AI

• Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain’s appetite control centers
• Financing will support the development of a dual-incretin-NMDA receptor antagonist conjugate through preclinical and early clinical development for the treatment of obesity

In conjunction with this financing, Prof. Sir Mene Pangalos, former Executive Vice President of BioPharmaceuticals R&D at AstraZeneca and current Omega Funds Venture Partner, as well as Dr. Elisabeth Bjӧrk, former Senior Vice President of Cardiovascular, Renal, and Metabolism R&D at AstraZeneca, and Dr. Otello Stampacchia, Founder and Managing Director of Omega Funds, will join Ousia’s Board of Directors

COPENHAGEN, Denmark and BOSTON, May 6, 2025 — Ousia Pharma, a next-generation biotech company pioneering a novel drug class for obesity, today announced the successful closing of a significant Seed financing round. The round, led and financed exclusively by Omega Funds, will support the preclinical and clinical development of Ousia’s innovative once-weekly, dual-incretin-NMDA receptor antagonist conjugate. Additionally, the funding will drive the expansion of Ousia’s proprietary technology, designed to target NMDA receptor small molecule modulators to specific neuronal populations.

While GLP-1-based multi-agonists are transforming obesity management, significant challenges remain, including tolerability issues, variability in patient weight loss response, and weight regain. These hurdles underscore the urgent need for more effective pharmacological approaches.

Ousia Pharma’s innovative targeting concept is founded on the groundbreaking discovery that NMDA receptor antagonism holds promise for sustained weight loss. By ingeniously overcoming the challenge of non-specific targeting, Ousia has developed a novel strategy that conjugates small-molecule modulators to incretin hormones (Petersen et al., 2024, Nature). This pioneering work began in the research lab of Associate Professor Christoffer Clemmensen at the University of Copenhagen, culminating in the founding of Ousia Pharma in 2022 by Christoffer Clemmensen, Anders B. Klein, and Jonas Petersen. The company secured its initial pre-seed investments from the BioInnovation Institute in Copenhagen.

“We are excited to enter the next phase of Ousia Pharma’s journey, advancing our groundbreaking platform towards clinical development,” said Anders B. Klein, PhD, CEO of Ousia Pharma. “The strong support from Omega Funds enables us to accelerate the preclinical and clinical validation of our peptide-drug conjugate program, bringing us closer to a transformative treatment for obesity. With a unique mechanism designed to enhance efficacy while addressing key challenges like tolerability, we believe our approach has the potential to set a new standard in obesity therapeutics.”

“We are thrilled to support Ousia Pharma as they advance a truly innovative approach to obesity treatment,” said Otello Stampacchia, founder and Managing Director at Omega Funds. “Their novel dual-incretin-NMDA receptor antagonist conjugate represents a promising breakthrough in tackling several of the limitations of existing obesity treatments. We believe Ousia’s pioneering science and accomplished team position the company for meaningful impact and value creation, and we are excited to be part of their journey.”

Otello Stampacchia, along with pharmaceutical industry veterans Dr. Elisabeth Björk and Prof. Sir Mene Pangalos, will join the Ousia Pharma board. Pangalos was previously Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, and Bjork was previously SVP of Cardiovascular, Renal, and Metabolism R&D at AstraZeneca, where she led the company’s GLP-1 drug development efforts. They will join existing board members Ian Laquian, CEO of Kariya Pharmaceuticals, and Christoffer Clemmensen, Associate Professor within the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen and Chief Scientific Officer at Ousia Pharma.

Prof. Sir Mene Pangalos said, “Having worked in the pharmaceutical industry for decades and witnessed many targets emerge and fade in the cardiometabolic space, I can confidently say that the approach taken by Ousia Pharma is one of the most innovative I have encountered. I am extremely excited to contribute to bringing Ousia Pharma’s technology to patients.”

About Ousia Pharma
Ousia Pharma, a private biotech company spun out from the University of Copenhagen, is developing innovative peptide-drug conjugates to treat obesity and metabolic diseases. The company has pioneered a first-in-class drug-targeting approach that leverages incretin hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain’s appetite control centers. This groundbreaking strategy aims to provide transformative treatments for patients suffering from obesity and its associated cardiometabolic conditions. For more information, please visit www.ousiapharma.com.

About Omega Funds
Founded in 2004, Omega Funds is a leading international venture capital firm that creates and invests in life sciences companies that target our world’s most urgent medical needs. Omega focuses on identifying and supporting companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption. Omega Funds’ portfolio companies have brought over 50 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others. Please visit www.omegafunds.com for additional information.

Contacts

Ousia Pharma
Anders Bue Klein
Co-founder & CEO, Ousia Pharma
E-mail: [email protected]

Omega Funds
Otello Stampacchia
Managing Director, Omega Funds
E-mail: [email protected]

SOURCE Ousia Pharma and Omega Funds

–  Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund

– Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-related dilated cardiomyopathy (LMNA DCM) through to clinical proof-of-concept

SINGAPORE and PHILADELPHIA, May 6, 2025 — Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the successful completion of US$45 million Series B financing. The round was co-led by Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio and Boehringer Ingelheim Venture Fund, alongside Highlight Capital and SEEDS Capital. Nuevocor is pleased to welcome Amanda Gett-Chaperot, PhD (Kurma Partners) and Elia Stupka, PhD (Angelini Ventures) to its Board of Directors.

The new investment will support a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM, with clinical trial sites across the U.S. and Europe. Additionally, the company will establish an office in Paris, France, to support clinical development and bring Singapore innovation to patients globally.

LMNA DCM is a genetic heart condition caused by mutations in the LMNA gene, leading to the weakening and enlargement of the heart muscle, ultimately resulting in a rapid progression toward end-stage heart failure. LMNA DCM is estimated to affect more than 100,000 patients in the U.S. and Europe. NVC-001 and other pipeline assets are derived from Nuevocor’s proprietary PrOSIA^TM mechanobiology platform, which pinpoints the functional root-cause of many cardiomyopathies.

“We are delighted to secure this significant financing milestone to build a global company with such an experienced syndicate of international life science investors,” said Dr. Yann Chong Tan, PhD, CEO and Co-Founder of Nuevocor. “The continued strong support from insiders and the addition of new investors will enable Nuevocor to continue its strong momentum and advance NVC-001 into the clinic. This is an example of how Singapore is bringing transformative innovation to the rest of the world.”

“Nuevocor is providing new hope to a significant population of cardiovascular patients who today lack treatment options by directly targeting the underlying causes of disease,” said Dr. Amanda Gett-Chaperot, Partner at Kurma Partners. “The burden of cardiomyopathies is large, and Kurma is excited to join Nuevocor, investing from our new Biofund IV to create meaningful value through the treatment of these important diseases.”

“Our investment in Nuevocor marks a strategic expansion for Angelini Ventures – into cardiovascular disease, gene therapy, and the Singapore biotech ecosystem. We are excited by Nuevocor’s novel approach to treating genetic-dilated cardiomyopathy by targeting mechanobiological pathways rather than simply replacing genes. This one-time therapy has the potential to transform patient outcomes and ease healthcare burdens. We are proud to support their mission and join the Board, alongside Kurma, ClavystBio, EDBI, Boehringer Ingelheim Venture Fund, and other investors, as the company grows globally, including into Europe,” said Dr. Elia Stupka, Managing Director at Angelini Ventures.

About NVC-001

NVC-001 is a first-in-class, AAV-based gene therapy candidate for the treatment of LMNA-related dilated cardiomyopathy (LMNA DCM), one of the most aggressive forms of  DCM with a rapid progression toward end-stage heart failure and malignant ventricular arrhythmias associated with increased risk of sudden cardiac death. LMNA DCM is estimated to affect more than 100,000 patients in the U.S. and Europe. NVC-001 is designed to reduce forces to the nucleus to restore nuclear envelope integrity, a hallmark of LMNA DCM, and treat disease. NVC-001 has demonstrated dramatic survival benefits in preclinical models, high transduction levels and a clean safety profile in both GLP toxicology studies and large animal models. Nuevocor plans to initiate a Phase 1/2 clinical trial in early 2026, with sites in the U.S. and Europe, and a concurrent natural history study.

About Nuevocor

Nuevocor is an IND-stage biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expanding to Europe. Our unique approach, enabled by our proprietary PrOSIA^TM mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options. (www.nuevocor.com)

About Kurma Partners

Founded in 2009 in Paris, Kurma Partners has become a key player in Europe, financing innovation to build the healthcare industry of tomorrow. Kurma invests from company formation to growth capital, across the spectrum of healthcare through specialized franchises. The franchises continue to expand with successive funds focused on biotechnology (Biofunds I, II, III, IV), digital health & diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and more recently, growth opportunities (Kurma Growth Opportunity Fund). Kurma’s teams based in Paris and Munich are embedded within the European ecosystem and have strong international networks spanning prestigious research institutes and hospitals, entrepreneurs, industry and investors. Kurma Partners is part of the Eurazeo group. (www.kurmapartners.com)

About Angelini Ventures

Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in biotech and digital health. Angelini Ventures will invest €300 million across a global portfolio, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested around €100 million into 18 companies covering a range of therapeutic areas and modalities. Its biotech portfolio includes Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The digital health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. (www.angeliniventures.com)

About EDBI

EDBI operates under SG Growth Capital, the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore. We invest in high-growth global technology companies and industry leaders looking to scale in Singapore and across Asia. Leveraging SG Growth Capital’s extensive networks and expertise, we collaborate with our portfolio companies to unlock growth opportunities, create pathways for advancement, and connect them with the resources needed for success. Through strategic investments and partnerships, we drive the development of innovative solutions, create good jobs, and contribute to Singapore’s long-term economic resilience. (www.edbi.com/) 

About ClavystBio

ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. Since our inception in 2022, ClavystBio has committed over US $220 million in investments in the life sciences sector. (www.clavystbio.com)  

About Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is dedicated to investing in groundbreaking biotechnology companies that are at the forefront of therapeutic and digital innovations, aiming to advance biomedical research. With a commitment to revolutionizing the standard of care, the BIVF fosters long-term partnerships with scientists and entrepreneurs. The BIVF’s focus is on nurturing disease-modifying therapeutic concepts and facilitating their clinical application. The BIVF prioritizes the translation of first-in-class concepts that address significant medical needs in fields such as oncology, immunology, regenerative medicine, neurodegeneration, infectious diseases, and digital health technologies. These innovative concepts often encompass novel platform technologies designed to tackle targets and diseases that were previously considered untreatable. With a fund volume of EUR 350 million, the BIVF operates as an evergreen fund, continually reinvesting to fuel its mission. The partners of the BIVF gain from the fund’s deep expertise in drug discovery & development, translational science, and management, along with access to a network of experts within the Boehringer Ingelheim organization. Currently, the BIVF supports a diverse portfolio of over 40 companies, leveraging its extensive experience to drive progress in healthcare. (www.boehringer-ingelheim-venture.com)

SOURCE Nuevocor

DETROIT, May 5, 2025 — In a landscape where less than 1% of venture capital goes to Black founders, Emmanuel Brown has led a $1.2 million raise to expand ChurchSpace, the mission-driven tech company. While Brown spearheaded the funding round, it’s Edwards’ deeply personal story—and unwavering vision—that continues to drive the soul of the company.

ChurchSpace helps churches transform underused buildings into income-generating hubs for events, outreach, and even last-mile delivery. With support from the City of Detroit, Mayor Mike Duggan, and investors like Black Ops Ventures, Minor Capital, and Michigan Rise, ChurchSpace is relocating its headquarters from Houston to Detroit to launch a citywide partnership and unlock the economic potential of sacred space.

“I watched my mom struggle just to serve,” said Day Edwards, CEO of ChurchSpace. “She built a church from the ground up, but the financial and emotional strain nearly broke our family. She prayed through overdue bills, stress, and sleepless nights—until she passed from a heart attack and stroke, still trying to keep the ministry going.”

In Texas, churches on the platform have earned up to $100,000 annually, reinvesting income into youth programs, food banks, and community outreach.

“When God gives vision, He makes provision,” Edwards continued. “This isn’t just tech—it’s about godly stewardship, economic justice, and making sure churches can serve and survive.”

“This raise is more than a business milestone—it’s a testament to what happens when strategy meets faith, when the odds are defied and purpose outweighs circumstance,” said Co-CEO Emmanuel Brown.

ChurchSpace is currently onboarding Detroit churches and preparing for a citywide partnership backed by the City of Detroit.

About ChurchSpace
ChurchSpace is a tech startup building smart logistics and shared-space solutions by activating underutilized church properties for business, ministry, and community impact.

FOR IMMEDIATE RELEASE
Contact: [email protected]
Website: www.bookchurchspace.com

SOURCE ChurchSpace Inc.

ROSEVILLE, Calif., May 5, 2025 — RightRev, a leader in automated revenue management, today announced the close of a $13 million Series A funding round, bringing total funding to over $31 million. The investment was co-led by Cheyenne Ventures and Innovius Capital, with notable participation from several repeat investors, including Norwest Venture Partners, Salesforce Ventures and Snowflake Ventures.

This investment follows RightRev’s recent recognition as a leader in the 2024 MGI Research Automated Revenue Management Buyers’ Guide. This showcases the company’s position as a trusted solution for enterprise organizations, such as Snowflake, the AI Data Cloud company, and Drata, which rely on RightRev to manage complex revenue scenarios across diverse industries.

The new capital will accelerate RightRev’s product innovation, go-to-market expansion and partner ecosystem growth as the company scales to meet the surging demand for revenue automation, especially in the AI era.

“Revenue management is no longer a back-office function—it’s a strategic capability,” said Jagan Reddy, CEO and founder of RightRev. “AI is enabling entirely new business models, from on-demand, consumption-based and outcome-driven, that create massive complexity in how companies recognize revenue. RightRev was purpose-built to handle this shift. With this funding and the backing of world-class investors, we’re doubling down on our mission to deliver speed, accuracy and intelligence to revenue teams around the world.”

Backed by Leading Investors
“As finance operations modernize, the demand for intelligent automation in revenue systems is accelerating,” said Justin Moore, CEO and founding partner at Innovius Capital. “RightRev transforms revenue recognition from a compliance burden into a source of insight and competitive advantage. With strong enterprise adoption, seamless integrations and a category-defining product, RightRev is poised to become the core system of record for revenue in the AI-powered enterprise.”

“Revenue recognition remains one of the most complex and mission-critical challenges in the back office. With unmatched domain expertise and a platform built to support high-volume, AI-driven business models, Jagan and the RightRev team have redefined the standard,” said Scott Beechuk, partner at Norwest. “We believe RightRev is uniquely positioned to shape the future of revenue automation.”

Setting the Bar for Revenue Management Excellence
RightRev’s platform combines deep expertise in revenue accounting with modern software architecture, enabling organizations to manage intricate revenue scenarios while ensuring compliance with ASC 606 and IFRS 15. In addition to its native integration with Salesforce Revenue Cloud, the platform seamlessly connects to upstream and downstream systems across the entire Order-to-Cash lifecycle. This flexibility enables finance teams to operate within their existing environments while benefiting from RightRev’s agility, high-volume processing capabilities and accuracy.

Fueling Innovation and Growth
The new funding will support:

• Expanding AI capabilities – Embedding AI across the platform to accelerate configuration, automate error detection and streamline high-volume data processing. RightRev’s AI engine powers real-time policy application, anomaly detection and faster implementations, reducing manual effort while increasing audit confidence.
• Supporting evolving business models – As companies shift toward on-demand, consumption-based and outcome-driven pricing, revenue recognition becomes exponentially more complex. RightRev is uniquely positioned to address this shift, automating compliance with ASC 606 and IFRS 15 while providing deep insight into current and future revenue performance.

• Accelerating market expansion – Scaling sales, marketing, partnerships and customer success to support growing enterprise demand. RightRev’s native integration with Salesforce Revenue Cloud and expanding support for other Order-to-Cash platforms and ERPs make it the ideal choice for finance teams navigating the shift to intelligent revenue infrastructure.

About RightRev
RightRev is a comprehensive platform to automate revenue management. The solution helps businesses streamline, recognize, report, analyze and comply with revenue standards. With a focus on speed, accuracy, and efficiency, the company continues to enhance its platform with artificial intelligence (AI) and new capabilities that simplify data migration, implementation and third-party integrations. Trusted by large enterprises and growth-stage companies across many industries, RightRev empowers finance teams to manage complex revenue scenarios and drive strategic growth. Founded in 2020, RightRev has raised more than $31 million from investors that include Norwest Venture Partners, Salesforce Ventures, Snowflake Ventures, Innovius Capital and Cheyenne Ventures.

For more information, visit www.RightRev.com.

SOURCE RightRev

Deerfield’s Healthcare Innovations Fund III will invest in promising therapeutics, improvements to healthcare delivery, and paradigm-shifting technologies

NEW YORK, May 5, 2025 — Deerfield Management Company, L.P., today announced the closing of the Deerfield Healthcare Innovations Fund III, a fund of over $600 million that aims to advance healthcare by investing in promising therapeutics, improving care delivery models, and elevating emerging technologies with the potential to shift existing paradigms, including machine learning and artificial intelligence.

“There has never been a better time to invest in new and evolving technologies and products across the life science, medical technology, and healthcare service landscape. Advancing knowledge, data, and software capabilities are transforming what is possible to achieve in improving health outcomes,” said James Flynn, Managing Partner at Deerfield.

Enabled by Deerfield’s collaborations with 29 leading research institutions and nine industry partners, Deerfield operationalizes innovation through its in-house ecosystem. Specialized teams like Deerfield Discovery and Development (3DC) and Deerfield Intelligence employ seasoned drug hunters, medical technology innovators, and software developers to identify and advance promising products, services, and technologies, often in partnership with Deerfield-founded entities like Deerfield Catalyst and Genscience.

Deerfield is housed at Cure, a twelve-story healthcare innovation campus located in New York City with a mission to accelerate cures by helping health innovators develop products and services from concept to commercialization. Cure’s resources include state-of-the-art research laboratories and convening spaces and is staffed to support health innovators’ business needs.

Deerfield recognizes that advancing healthcare requires more than a for-profit investment model can provide. In keeping with the firm’s long-standing practice, Healthcare Innovations Fund III will donate a portion of profits not allocated to the fund’s limited partners to the Deerfield Foundation, a not-for-profit organization focused on improving the health of children worldwide. Since its inception in 2005, the Deerfield Foundation has partnered with a diverse slate of healthcare-focused non-profits to make a difference in the lives of patients and families, from clinics in the South Bronx to care facilities in the highlands of Nepal. Foundation funds are provided via employee contributions as well as fund profits.

Deerfield has invested in and supported the healthcare industry for over 30 years. Today the firm employs more than 180 professionals, with specialized knowledge that spans clinical and translational medicine, drug and medical device development, healthcare policy and markets, machine learning and data science, biostatistics, value-based care, financial instruments, operations, corporate strategy, market access research, sector dynamics, and more, which can be leveraged by corporate and strategic partners.

About Deerfield Management

Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas, and technology in bold, collaborative, and inclusive ways. For more information, please visit www.deerfield.com.

Contact
Jessica Sagers, PhD, Head of Communications
[email protected]

SOURCE Deerfield Management Company, L.P.

DETROIT, May 5, 2025 — In a bold move blending faith, innovation, and economic revitalization, ChurchSpace has announced the close of a $1.2 million oversubscribed funding round, led by Black Ops Ventures, with additional participation from Dug Song of Minor Capital and Michigan Rise.

The startup is also relocating its national headquarters from Houston, Texas, to Detroit, Michigan — a city known for its rich spiritual legacy and entrepreneurial spirit — to deepen its mission of activating underutilized sacred spaces for modern-day community use.

As part of its national growth, ChurchSpace has also launched a historic partnership with the City of Detroit. This groundbreaking initiative will activate church campuses across Detroit not only as flexible event spaces and business hubs but also as micro-logistics and last-mile delivery centers — positioning churches as powerful engines of economic development, job creation, and community support.

“This raise is more than a business milestone—it’s a testament to what happens when strategy meets faith. In today’s climate, raising capital takes grit and resilience—especially without deep networks or traditional access. By God’s grace, doors have opened, and our mission is clearer than ever. Now, with capital in hand, we’re building boldly toward a future where the Church isn’t just surviving—but leading community transformation. We’re deeply grateful to our investors, supporters, champions, and our incredible team,” said Emmanuel Brown, Co-CEO of ChurchSpace.

“What we built in Houston was more than technology—it was transformation. We expanded our purpose and packaged proven strategies to help churches thrive, transform communities, and even combat food insecurity. Now, with prayer and the support of our team and investors, we’re bringing that same impact to Detroit—to help churches, communities, and small businesses redefine pulpits and rediscover communal possibilities,” said Day Edwards, Founder of ChurchSpace.

Through this new model, ChurchSpace is equipping churches to host local businesses, pop-up markets, and community events while also serving as fulfillment hubs for food distribution, retail partnerships, and last-mile delivery services. By using existing, often underutilized real estate inside church campuses — such as fellowship halls, kitchens, and classrooms — ChurchSpace unlocks new streams of passive income for churches while helping small businesses reach local consumers faster and more affordably.

Already, churches on the ChurchSpace platform in Texas have generated up to $100,000 annually in new revenue—funds that have been reinvested into ministries, food programs, and community initiatives. In Detroit, ChurchSpace projects hundreds of direct and indirect jobs will be created in logistics support, delivery management, event hosting, and technical services.

Mayor Mike Duggan praised the partnership, noting the longstanding role churches have played in Detroit’s community fabric.

“We welcome ChurchSpace’s investment in Detroit and the jobs and innovation it will bring. Our faith community has long been a critical backbone of our neighborhoods. Through ChurchSpace’s groundbreaking work, they will continue to be anchors of opportunity and resilience in our city’s future,” said Mayor Mike Duggan.

Investors also praised the vision behind ChurchSpace’s mission:

“From Motown to ministry, Detroit’s always had soul. ChurchSpace is bringing fresh tech to sacred spaces—helping churches thrive, serve, and connect across communities. We’re proud to support their mission and welcome them to Detroit,” said Dug Song, of Minor Capital.

“ChurchSpace is leveraging technology and network effects to transform underutilized space into a powerful resource for communities. We’re thrilled to support their growth, especially as they start making an impact in Michigan,” said Pete Martin, Director of Portfolio Management at Michigan Rise.

“This investment is about more than scaling a platform—it’s about scaling hope, resilience, and opportunity at the neighborhood level. ChurchSpace is exactly the kind of visionary innovation Black Ops Ventures is proud to back,” said Antonia Dean, Principal at Black Ops Ventures.

Churches across Detroit are invited to apply to participate in the pilot program. Selected churches will be onboarded, equipped with new tools for space sharing, revenue generation, and logistics support, and will play a key role in building Detroit’s next chapter of faith-powered economic growth.

To kick off the launch, ChurchSpace will host its Detroit Pastor Meetup on July 19, 2025 — an invitation-only lunch and learn event for pastors and church administrators to learn about ChurchSpace’s model, share their needs, and begin building customized community solutions.

Interested churches can RSVP here:
 RSVP LINK

About ChurchSpace
 ChurchSpace is a tech startup building smart solutions for shared space and logistics through underutilized community infrastructure, helping churches transform their available real estate into purpose-filled spaces for businesses and the community.

Learn more: 

[www.bookchurchspace.com]

Press Contact:
[email protected]

SOURCE ChurchSpace Inc.